TLR4 and acute myeloid leukemia: Future clinical studies of TLR4 targeting in AML should therefore include detailed biological characterization of both bone marrow MSCs/osteoblasts and AML cells to further investigate (i) the molecular mechanisms responsible for the prognostic impact of TLR4; (ii) the molecular crosstalk between leukemic and stromal cells; and (iii) how these mechanisms differ between patients and whether TLR4 targeting will be effective only in certain subsets of AML patients [120].